Vitrolife (Sweden) Insiders
| VITR Stock | SEK 234.60 14.00 5.63% |
Vitrolife employs about 1.1 K people. The company is managed by 7 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 153.29 employees per reported executive. Breaking down Vitrolife's management performance can provide insight into the firm performance.
| Rickard Ericsson President Vice President Market Region EMEA & Americas |
Vitrolife |
Vitrolife Management Team Effectiveness
The company has return on total asset (ROA) of 0.0205 % which means that it generated a profit of $0.0205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0246 %, meaning that it generated $0.0246 on every $100 dollars invested by stockholders. Vitrolife's management efficiency ratios could be used to measure how well Vitrolife manages its routine affairs as well as how well it operates its assets and liabilities.Vitrolife Workforce Comparison
Vitrolife AB is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 11,428. Vitrolife holds roughly 1,073 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2. Vitrolife AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Vitrolife AB Price Series Summation is a cross summation of Vitrolife price series and its benchmark/peer.
Vitrolife Notable Stakeholders
A Vitrolife stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vitrolife often face trade-offs trying to please all of them. Vitrolife's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vitrolife's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Rickard Ericsson | Vice President Market Region EMEA & Americas | Profile | |
| Daniel Forss | VP Consumables | Profile | |
| Claus Bisgaard | VP Technologies | Profile | |
| Ricardo Capella | VP Services | Profile | |
| Karin Russberg | VP Sustainability | Profile | |
| Patrik Tolf | Chief Officer | Profile | |
| Thomas MSc | Pres CEO | Profile |
About Vitrolife Management Performance
The success or failure of an entity such as Vitrolife AB often depends on how effective the management is. Vitrolife management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vitrolife management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vitrolife management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vitrolife AB , a medical device company, develops, produces, and markets products for assisted reproduction. Vitrolife AB was founded in 1981 and is headquartered in Gothenburg, Sweden. Vitrolife operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 415 people.
Please note, the imprecision that can be found in Vitrolife's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vitrolife AB. Check Vitrolife's Beneish M Score to see the likelihood of Vitrolife's management manipulating its earnings.
Vitrolife Workforce Analysis
Traditionally, organizations such as Vitrolife use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vitrolife within its industry.Vitrolife Manpower Efficiency
Return on Vitrolife Manpower
| Revenue Per Employee | 1.6M | |
| Revenue Per Executive | 240.1M | |
| Net Income Per Employee | 317.8K | |
| Net Income Per Executive | 48.7M | |
| Working Capital Per Employee | 304.8K | |
| Working Capital Per Executive | 46.7M |
Additional Tools for Vitrolife Stock Analysis
When running Vitrolife's price analysis, check to measure Vitrolife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitrolife is operating at the current time. Most of Vitrolife's value examination focuses on studying past and present price action to predict the probability of Vitrolife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitrolife's price. Additionally, you may evaluate how the addition of Vitrolife to your portfolios can decrease your overall portfolio volatility.